← back to search

Mohammed Alshalalfa

University of California, San Francisco · US
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer, Lipids, and Metabolism, and Ferroptosis and cancer prognosis.
h-index
39
citations
5,482
works
309
NIH funding
primary concept
email

Recent publications

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Nature Genetics 2025cited by 3position: middledoi
Pan-cancer genomic analysis reveals <i>FOXA1</i> amplification is associated with adverse outcomes in non–small cell lung, prostate, and breast cancers
JNCI Journal of the National Cancer Institute 2024cited by 8position: middledoi
Racial Disparities in Glioblastoma Genomic Alterations: A Comprehensive Analysis of a Multi-Institution Cohort of 2390 Patients
World Neurosurgery 2024cited by 6position: middledoi
Disparities in Diagnosis, Treatment Access, and Time to Treatment Among Hispanic Men With Metastatic Prostate Cancer
JCO Oncology Practice 2023cited by 16position: middledoi
Genomic Characterization of Aggressive Breast Cancer in Younger Women
Annals of Surgical Oncology 2023cited by 14position: middledoi
Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors
Urologic Oncology Seminars and Original Investigations 2023cited by 8position: firstdoi
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men
Prostate Cancer and Prostatic Diseases 2022cited by 28position: middledoi
Racial Differences in Genomic Profiles of Breast Cancer
JAMA Network Open 2022cited by 27position: lastdoi
Clinicogenomic characterization of prostate cancer liver metastases
Prostate Cancer and Prostatic Diseases 2022cited by 19position: firstdoi
Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis
Urologic Oncology Seminars and Original Investigations 2022cited by 7position: firstdoi
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Nature Communications 2021cited by 129position: middledoi
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
Nature Communications 2021cited by 104position: middledoi
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
Communications Biology 2021cited by 84position: middledoi
Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Clinical Cancer Research 2021cited by 30position: middledoi
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer
European Urology 2021cited by 18position: middledoi
The DNA methylation landscape of advanced prostate cancer
Nature Genetics 2020cited by 349position: middledoi
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
Nature Communications 2020cited by 146position: middledoi
Racial Differences in Genomic Profiling of Prostate Cancer
New England Journal of Medicine 2020cited by 125position: middledoi
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance
Nature Cancer 2020cited by 82position: middledoi
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program
Nature Communications 2019cited by 180position: middledoi
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Clinical Cancer Research 2019cited by 128position: middledoi
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types
Clinical Cancer Research 2019cited by 61position: middledoi
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer
EBioMedicine 2018cited by 158position: middledoi
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
GigaScience 2018cited by 78position: middledoi
The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer
European Urology 2018cited by 77position: middledoi
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
JAMA Oncology 2017cited by 311position: middledoi
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
Cell Reports 2017cited by 134position: middledoi
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Clinical Cancer Research 2017cited by 109position: middledoi
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
Cancer Research 2016cited by 226position: middledoi
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis
The Lancet Oncology 2016cited by 216position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Brandon A. Mahal · University of Miami14 papers (2019–2024)Elai Davicioni · Coherus BioSciences (United States)14 papers (2014–2021)Nicholas Erho · NewYork–Presbyterian Hospital10 papers (2015–2018)Paul L. Nguyen · Harvard University9 papers (2016–2024)Felix Y. Feng · Polytechnique Montréal9 papers (2014–2021)Edward M. Schaeffer · Northwestern University7 papers (2015–2021)Ashley E. Ross · Northwestern University6 papers (2015–2021)R. Jeffrey Karnes · Mayo Clinic6 papers (2015–2021)Daniel E. Spratt · Drexel University6 papers (2016–2022)Shuang G. Zhao · University of Wisconsin Carbone Cancer Center6 papers (2015–2021)Nishwant Swami · Hospital of the University of Pennsylvania6 papers (2022–2024)Robert B. Den · Thomas Jefferson University5 papers (2015–2019)Edward Christopher Dee · University of North Texas5 papers (2022–2024)Sanoj Punnen · University of Miami5 papers (2016–2024) · 4 papers (2022–2023)Peter R. Carroll · UCSF Helen Diller Family Comprehensive Cancer Center4 papers (2016–2021)Matthew R. Cooperberg · UCSF Helen Diller Family Comprehensive Cancer Center4 papers (2016–2021)Tiffany Nguyen · UC San Diego Health System3 papers (2022–2023)Amar U. Kishan · University of Colorado Denver3 papers (2021–2023)Adam P. Dicker · Thomas Jefferson University3 papers (2015–2019)